Objective To explore the diagnostic values of serum carbohydrate antigen CA242, CA125 and CA199 in GI tumors.
目的探讨血清中CA242、CA125、CA199含量对消化系肿瘤中的诊断价值。
The levels of expression of CA242 and CA19-9 in carcinoma of colon and rectal carcinoma were with significant differences.
CA19蛳9分别在结肠癌和直肠癌中的表达水平不同，其差异具有显著性意义。
Laboratory investigations of some patients showed decreased pancreatic exocrine function and elevated CA242 of tumor markers.
实验室检查部分患者可出现胰腺外分泌功能下降，肿瘤标记物ca242轻度升高。
Conclusion: The value of CA242, CA19-9 and CEA by application of protein chip diagnosis system is reliable, with ideal diagnostic value.
结论蛋白芯片法检测CA242,CA19 - 9和CEA结果可靠，对胰腺癌的诊断有一定的价值。
Objective: To investigate the clinical value of CA242 and CA19-9 (tumor marker) in the diagnosis, treatment and prognosis of colorectal cancer.
目的：评价肿瘤标志物CA242与CA19 - 9在大肠癌诊断、治疗和预后中的临床意义。
Methods Preoperative serum CEA, CA19-9, and CA242 were measured in 105 pancreatic cancer, 70 non-pancreatic malignance, and 30 benign pancreatic diseases.
方法回顾性分析了105例胰腺癌患者，70例非胰腺外分泌恶性肿瘤以及30例胰腺良性疾病患者术前血清CEA、CA19-9和CA242水平。
Objective: Detection of P53, CA242 proteins in pancreatic carcinoma tissues may offer some important information for early diagnosis, therapy and prognosis of this disease.
目的：检测P53蛋白、CA242标记分子在原发性胰腺癌及良性病变中的变化，为早期诊断、治疗和评价预后提供分子病理学客观的参考依据。
Objective To observe the changes of the levels of serum tumor markers, i. e. CA19-9, CA242 and CEA, and their significance during the interventional chemotherapy for pancreatic carcinoma.
目的观察胰腺肿瘤介入化疗术前后相关血清肿瘤标志物糖链抗原19 9（CA19 9）、糖类抗原2 4 2（CA2 4 2 ）及癌胚抗原（CEA）的水平变化及其意义。
Objective To probe the clinical evaluation of tumor specific growth factor(TSGF), carbohydrate 19-9(CA19-9) and carbohydrate 242(CA242) combinedly in detecting malignant tumors in digestive tract.
目的探讨用恶性肿瘤特异性生长因子（TSGF）、糖抗原19 9（CA19 9）与糖抗原2 42 （CA2 42 ）联合检测对消化道恶性肿瘤的临床评价。
Objective To probe the clinical evaluation of tumor specific growth factor(TSGF), carbohydrate 19-9(CA19-9) and carbohydrate 242(CA242) combinedly in detecting malignant tumors in digestive tract.
目的探讨用恶性肿瘤特异性生长因子（TSGF）、糖抗原19 9（CA19 9）与糖抗原2 42 （CA2 42 ）联合检测对消化道恶性肿瘤的临床评价。
应用推荐